Issa Mohamed Khairie's Form 4 filing
Incyte CorpINCY · filed Jan 8, 2026
- Accession no.
- 0002050035-26-000002
- Filed
- Jan 8, 2026
- Trade date
- Jan 6-7, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions. Open-market sales total $1.18M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Issa Mohamed KhairieCIK 0002050035 | Officer (EVP, Head of US Oncology) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 6, 2026 | Common Stock | FTax withholdingDisposed | −8,264 | $106.66 | −$881,438.24 | 76,988 | Direct | |
| Jan 7, 2026 | Common Stock | SSaleDisposed | −10,856 | $109.07 | −$1,184,063.92 | 66,132 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.